Figure 1

Cumulative off-treatment virologic relapse rate. The relapse rates at 12 and 24 months were 73.8% and 87.1%, respectively in patients with CHB who achieved complete viral suppression with oral nucleos(t)ide analog (NA) therapy (A). The relapse rates were similar regardless of HBeAg status (B), HBeAg seroconversion (for pre-treatment HBeAg-positive patients who subsequently lost HBeAg during treatment) (C), and the type of oral NA: lamivudine 100 mg/day; clevudine 30 mg/day; entecavir 0.5 mg/day (D). The relapse rates were not significantly different between HBeAg-positive patients with <24 months and >24 months of treatment (E). However, the relapse rates were higher in HBeAg-negative patients who received >24 months of antiviral therapy compared with patients with shorter treatment duration (F).